China's overall surgical robot market is projected to grow at a compound annual growth rate (CAGR) of approximately 34% from 2024 to 2032E. According to data from Frost & Sullivan and Edge Medical's IPO prospectus, the market size is expected to expand from RMB 7.2 billion in 2024 to RMB 76.7 billion by 2032. Driven by factors such as increasing penetration rates, the surgical robot market holds significant potential, with high growth anticipated for the industry. Among segments, laparoscopic surgical robots are expected to achieve a CAGR of about 29% from 2024 to 2032E, catalyzed by the relaxation of configuration permits and the implementation of fee schedules. The adoption of fee schedules is likely to accelerate hospital admissions, leading to a continuous rise in the penetration rate of orthopedic surgical robots. Data from Frost & Sullivan and Weizhuo Zhiyuan's public transfer document indicate a projected CAGR of around 41% for this segment from 2024 to 2032E. Zheshang Securities released a report stating that the surgical robot market offers substantial growth opportunities, supported by increasing penetration rates, and the industry is poised for rapid expansion. The institution believes that the implementation of fee schedules could speed up the adoption of surgical robots in hospitals, with laparoscopic and orthopedic surgical robots potentially entering a phase of rapid development by 2026. The overseas surgical robot market is vast and currently experiencing rapid growth, with leading domestic companies expected to achieve significant overseas growth by 2026, potentially forming a sustained new growth driver. Optimism surrounds the inflection point for volume growth of domestic surgical robots in 2026, driven by the implementation of fee schedules and accelerated overseas expansion. Companies with strong commercial capabilities, including platform-based surgical robot firms and upstream manufacturers, are viewed favorably. China Securities (CSC) considers surgical robots one of the best business models in the medical device sector, as equipment installation leads to continuous consumables sales, generating stable revenue and cash flow. Globally, the leading comparable company Intuitive Surgical has a market capitalization exceeding RMB 1 trillion, and there remains considerable room for growth in both penetration rates and market size. Overseas leaders dominate the market due to first-mover advantages, while domestic leaders are accelerating product iterations, with performance nearing global advanced levels and leading in remote surgery applications. Overseas business already constitutes a major portion of revenue for these companies and continues to grow rapidly, suggesting significant potential for both revenue and market capitalization expansion. CSC also highlights that AI is expected to empower surgical robots to achieve autonomous operations, further assisting or replacing certain surgical procedures performed by doctors, which could benefit industry penetration rates and enhance the valuations of related companies. Hong Kong-listed stocks related to surgical robots include: EDGE MEDICAL-B (02675), MEDBOT-B (02252), and KANGJI MEDICAL (09997).